|
Patients, n
|
179
|
336
|
515
|
18
|
59
|
77
|
|
Age, years
|
49.5 ± 9.9
|
48.7 ± 10.7
|
49.0 ± 10.4
|
70.4 ± 3.4
|
70.1 ± 4.3
|
70.2 ± 4.1
|
|
Female
|
141 (78.8)
|
276 (82.1)
|
417 (81.0)
|
16 (88.9)
|
50 (84.7)
|
66 (85.7)
|
|
Race
|
|
Caucasian
|
145 (81.0)
|
272 (81.2)
|
417 (81.1)
|
15 (83.3)
|
43 (72.9)
|
58 (75.3)
|
|
Asian
|
10 (5.6)
|
30 (9.0)
|
40 (7.8)
|
2 (11.1)
|
1 (1.7)
|
3 (3.9)
|
|
Black
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
1 (1.7)
|
1 (1.3)
|
|
Other
|
24 (13.4)
|
33 (9.8)
|
57 (11.1)
|
1 (5.6)
|
14 (23.7)
|
15 (19.5)
|
|
Weight, kg
|
71.7 ± 17.4
|
72.4 ± 16.2
|
72.2 ± 16.6
|
73.8 ± 15.3
|
66.3 ± 14.3
|
68.1 ± 14.7
|
|
BMI, kg/m2
|
26.9 ± 5.7
|
27.0 ± 5.6
|
27.0 ± 5.6
|
28.3 ± 5.5
|
25.8 ± 4.9
|
26.4 ± 5.1
|
|
RA disease duration
|
6.6 ± 6.3
|
6.5 ± 6.3
|
6.5 ± 6.3
|
10.8 ± 13.1
|
9.3 ± 9.8
|
9.7 ± 10.6
|
|
ACR core components
|
|
Number of swollen joints (0–68)
|
14.7 ± 8.4
|
15.0 ± 8.5
|
14.9 ± 8.5
|
15.9 ± 9.8
|
14.6 ± 6.2
|
14.9 ± 7.2
|
|
Numbers of tender joints (0–68)
|
25.9 ± 14.3
|
26.6 ± 13.7
|
26.3 ± 13.9
|
25.8 ± 12.8
|
25.5 ± 15.2
|
25.6 ± 14.6
|
|
CRP, mg/dL
|
2.3 ± 1.9
|
2.8 ± 2.7
|
2.6 ± 2.5
|
1.5 ± 1.1
|
3.1 ± 3.7
|
2.7 ± 3.4
|
|
Physician’s global assessment (VAS, 0–10 cm)
|
6.3 ± 1.5
|
6.3 ± 1.6
|
6.3 ± 1.6
|
5.9 ± 2.0
|
6.0 ± 1.7
|
5.9 ± 1.7
|
|
Patient’s global assessment (VAS, 0–10 cm)
|
6.5 ± 1.9
|
6.5 ± 1.8
|
6.5 ± 1.9
|
6.2 ± 2.2
|
6.3 ± 1.8
|
6.3 ± 1.9
|
|
Patient’s assessment of pain (VAS, 0–10 cm)
|
6.5 ± 2.0
|
6.5 ± 1.9
|
6.5 ± 1.9
|
6.6 ± 2.0
|
6.5 ± 1.6
|
6.5 ± 1.7
|
|
HAQ-DI
|
1.60 ± 0.60
|
1.55 ± 0.66
|
1.56 ± 0.64
|
1.35 ± 0.72
|
1.61 ± 0.71
|
1.55 ± 0.72
|
|
Anti-CCP antibodies
|
165/177 (93.2)
|
307/335 (91.6)
|
472/512 (92.2)
|
16 (88.9)
|
55 (93.2)
|
71 (92.2)
|
|
Rheumatoid factor
|
164 (91.6)
|
309 (92.0)
|
473 (91.8)
|
17 (94.4)
|
56 (94.9)
|
73 (94.8)
|
|
SF-36 PCS
|
30.8 ± 7.2
|
31.0 ± 6.6
|
30.9 ± 6.8
|
31.7 ± 8.9
|
30.0 ± 7.8
|
30.4 ± 8.0
|
|
SF-36 MCS
|
38.3 ± 11.7
|
36.8 ± 11.1
|
37.3 ± 11.3
|
41.0 ± 10.4
|
38.9 ± 11.1
|
39.4 ± 10.9
|
|
Concomitant medications
|
|
MTX dose at screening
|
16.7 ± 2.8
|
16.9 ± 2.9
|
16.8 ± 2.9
|
16.4 ± 2.9
|
16.3 ± 2.8
|
16.3 ± 2.8
|
|
Duration of MTX use
|
|
< 1 year
|
44 (24.6)
|
82 (24.4)
|
126 (24.5)
|
4 (22.2)
|
20 (33.9)
|
24 (31.2)
|
|
1 to < 3 years
|
53 (29.6)
|
97 (28.9)
|
150 (29.1)
|
8 (44.4)
|
17 (28.8)
|
25 (32.5)
|
|
≥ 3 years
|
82 (45.8)
|
154 (45.8)
|
236 (45.8)
|
6 (33.3)
|
22 (37.3)
|
28 (36.4)
|
|
Unknown
|
0 (0.0)
|
3 (0.9)
|
3 (0.6)
|
0 (0.0)
|
0 (0.0)
|
0 (0.0)
|
|
Oral corticosteroids
|
121 (67.6)
|
221 (65.8)
|
342 (66.4)
|
13 (72.2)
|
30 (50.8)
|
43 (55.8)
|
|
Dose (prednisone or equivalent), mg/day
|
7.0 ± 2.5
|
7.1 ± 2.5
|
7.0 ± 2.5
|
6.9 ± 2.7
|
6.6 ± 2.7
|
6.7 ± 2.6
|
|
NSAIDs
|
145 (81.0)
|
280 (83.3)
|
425 (82.5)
|
11 (61.1)
|
43 (72.9)
|
54 (70.1)
|
|
Prior medications
|
|
DMARDs*
|
83 (46.4)
|
182 (54.2)
|
265 (51.5)
|
9 (50.0)
|
24 (40.7)
|
33 (42.9)
|
